SELLAS Announces It Met Primary, Secondary Endpoint In Lymphoma Cohort From SLS009 Phase 1 Dose-Escalation Trial
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Group, Inc. (SLS) announced that it met the primary and secondary endpoint in the lymphoma cohort from its SLS009 Phase 1 dose-escalation trial. The trial enrolled 52 relapsed and refractory lymphoma patients, with 96% alive at the last assessment, indicating a favorable survival benefit. The company observed responses across dose levels with a 14.7% clinical response rate overall, a 35.3% overall disease control rate, and a 36.4% clinical response rate in PTCL patients. The recommended Phase 2 dose for lymphoma patients has been established at 100 mg once per week.
September 21, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences Group, Inc. (SLS) met the primary and secondary endpoint in its SLS009 Phase 1 dose-escalation trial for lymphoma patients. This positive outcome could potentially boost investor confidence and positively impact the company's stock price in the short term.
Positive clinical trial results often lead to increased investor confidence as they indicate progress in the company's research and development efforts. This can lead to increased demand for the company's stock, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100